X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (42) 42
humans (41) 41
immunotherapy (34) 34
nivolumab (30) 30
aged (25) 25
male (25) 25
oncology (24) 24
melanoma (22) 22
programmed cell death 1 receptor - antagonists & inhibitors (22) 22
cancer (21) 21
female (18) 18
ipilimumab (18) 18
middle aged (17) 17
antibodies, monoclonal - adverse effects (16) 16
apoptosis (16) 16
care and treatment (16) 16
dermatology (16) 16
adult (13) 13
chemotherapy (13) 13
melanoma - drug therapy (13) 13
patients (13) 13
pembrolizumab (13) 13
treatment outcome (13) 13
antibodies, monoclonal - therapeutic use (12) 12
antineoplastic agents - adverse effects (12) 12
case report (12) 12
metastasis (12) 12
safety (12) 12
aged, 80 and over (11) 11
antineoplastic agents - therapeutic use (11) 11
metastatic melanoma (11) 11
skin neoplasms - drug therapy (11) 11
programmed cell death 1 receptor - immunology (10) 10
antibodies, monoclonal, humanized - adverse effects (9) 9
survival (9) 9
therapy (9) 9
anti-programmed death-1 (8) 8
antibodies, monoclonal, humanized - therapeutic use (8) 8
antibody (8) 8
expression (8) 8
immune checkpoint (8) 8
medicine, research & experimental (8) 8
open-label (8) 8
prognosis (8) 8
skin neoplasms - pathology (8) 8
anti-programmed cell death-1 (7) 7
antigens (7) 7
development and progression (7) 7
lung neoplasms - drug therapy (7) 7
retrospective studies (7) 7
tumors (7) 7
young adult (7) 7
abridged index medicus (6) 6
antibodies (6) 6
antineoplastic agents, immunological - therapeutic use (6) 6
cancer therapies (6) 6
cells (6) 6
drug therapy (6) 6
immunotherapy - methods (6) 6
lung cancer (6) 6
lung neoplasms - pathology (6) 6
lymphocytes (6) 6
melanoma - pathology (6) 6
neoplasms. tumors. oncology. including cancer and carcinogens (6) 6
research (6) 6
t cells (6) 6
usage (6) 6
advanced melanoma (5) 5
anti-pd-1 (5) 5
anti-programmed death-1 antibody (5) 5
article (5) 5
cell death (5) 5
disease-free survival (5) 5
metastases (5) 5
pd-1 blockade (5) 5
programmed cell death 1 receptor - metabolism (5) 5
radiation therapy (5) 5
survival rate (5) 5
analysis (4) 4
animals (4) 4
antibodies, monoclonal - administration & dosage (4) 4
antineoplastic agents (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic agents, immunological - adverse effects (4) 4
b7-h1 antigen - antagonists & inhibitors (4) 4
biochemistry (4) 4
biomarkers (4) 4
blockade (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
carcinoma, renal cell - drug therapy (4) 4
carcinoma, squamous cell - drug therapy (4) 4
cell lung-cancer (4) 4
clinical trials (4) 4
ctla-4 antigen - antagonists & inhibitors (4) 4
diabetes (4) 4
diagnosis (4) 4
efficacy (4) 4
follow-up studies (4) 4
gene expression (4) 4
health aspects (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Diabetes Investigation, ISSN 2040-1116, 11/2016, Volume 7, Issue 6, pp. 915 - 918
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 5, pp. 863 - 870
Journal Article
Journal Article
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 12/2019, Volume 14, Issue 12, pp. 2071 - 2083
Introduction: Programmed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of... 
Biomarker | NSCLC | LUNG ADENOCARCINOMA PATIENTS | INDUCTION | CANCER | Anti-programmed death 1 therapy | BIOMARKERS | ONCOLOGY | GAGED2A | IMMUNOTHERAPY | RESPIRATORY SYSTEM | Serum antibody | Cancer-testis antigen | PD-1 | EXPRESSION | IMMUNE-CHECKPOINT BLOCKADE | T-CELLS
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 85, pp. 67 - 77
Hodgkin lymphoma (HL) was one of the first few cancers to be cured first with radiotherapy alone and then with a combination of chemotherapy and radiotherapy.... 
Anti-programmed death 1 | Hodgkin lymphoma | REED-STERNBERG CELLS | EBV INFECTION | PD-1 BLOCKADE | BRENTUXIMAB VEDOTIN | OPEN-LABEL | SINGLE-ARM | Anti-programmed | death 1 | PHASE-II TRIAL | ONCOLOGY | TUMOR-ASSOCIATED MACROPHAGES | EXPRESSION | T-CELLS | Tumor Escape - drug effects | Immunotherapy - methods | Hodgkin Disease - genetics | Humans | Middle Aged | Tumor Microenvironment | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Reed-Sternberg Cells - drug effects | Biomarkers, Tumor - antagonists & inhibitors | Child | Antibodies - therapeutic use | Hodgkin Disease - metabolism | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Antibodies - adverse effects | Reed-Sternberg Cells - immunology | Immunotherapy - adverse effects | Reed-Sternberg Cells - metabolism | Signal Transduction - drug effects | Hodgkin Disease - therapy | Adolescent | Hodgkin Disease - immunology | Aged | Biomarkers, Tumor - genetics | Programmed Cell Death 1 Receptor - immunology | Biomarkers, Tumor - immunology | Antigens | Chemotherapy | Cell death | Immunotherapy | Respiratory tract diseases | Lymphomas | Drug therapy | T cells | Radiotherapy | Cancer | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 12/2018, Volume 105, pp. 88 - 102
Journal Article
Cancer, ISSN 0008-543X, 09/2017, Volume 123, Issue 17, pp. 3285 - 3290
BACKGROUND Immunotherapy has changed the therapeutic landscape in oncology. Advanced uterine leiomyosarcoma (ULMS) remains an incurable disease in most cases,... 
uterine leiomyosarcoma | sarcoma | nivolumab | immunotherapy | anti–programmed‐death 1 (PD‐1) | anti–programmed-death 1 (PD-1) | CELLS | EFFICACY | SAFETY | PD-L1 EXPRESSION | DOCETAXEL | PEMBROLIZUMAB | anti-programmed-death 1 (PD-1) | ONCOLOGY | SARCOMAS | BLOCKADE | IPILIMUMAB | Prognosis | Age Factors | Uterine Neoplasms - pathology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Uterine Neoplasms - mortality | Adult | Female | Retrospective Studies | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Leiomyosarcoma - pathology | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Survival Analysis | Uterine Neoplasms - drug therapy | Leiomyosarcoma - mortality | Leiomyosarcoma - drug therapy | Aged | Infusions, Intravenous | Neoplasm Staging | Cohort Studies | Usage | Uterus | Immunotherapy | Leiomyosarcoma | Research | Gene expression | Drug therapy | Health aspects | Health care | Intravenous administration | Statistical analysis | Sarcoma | PD-1 protein | Toxicity | Immunomodulation | Tumor cells | Phenotypic variations | Statistical methods | Patients | Survival | Modulators | Confidence intervals | Population (statistical) | Immune checkpoint | PD-L1 protein | Phenotyping | Biomarkers | Toxic diseases | Cancer | Immune system | Index Medicus | Abridged Index Medicus | programmed-death 1 (PD-1) | anti
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3354 - 3362
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 11/2017, Volume 97, Issue 10, pp. 1212 - 1218
Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic... 
NRAS | BRAF | Circulating tumour DNA | Droplet digital PCR | Anti-programmed cell death-1 antibody | Melanoma | DIGITAL PCR | melanoma | NRAS MUTATIONS | CANCER | DERMATOLOGY | METASTATIC MELANOMA | anti-programmed cell death-1 antibody | THERAPY | PLASMA | circulating tumour DNA | droplet digital PCR | RESISTANCE | NIVOLUMAB | UTILITY | Melanoma - blood | Predictive Value of Tests | Immunotherapy - methods | Skin Neoplasms - drug therapy | Circulating Tumor DNA - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Tomography, X-Ray Computed | Cell-Free Nucleic Acids - genetics | Drug Monitoring - methods | Skin Neoplasms - blood | Time Factors | DNA Mutational Analysis | Melanoma - genetics | Aged, 80 and over | Female | Skin Neoplasms - immunology | Treatment Outcome | Biomarkers, Tumor - blood | Antineoplastic Agents, Immunological - therapeutic use | Melanoma - immunology | Proto-Oncogene Proteins B-raf - genetics | Cell-Free Nucleic Acids - blood | Melanoma - drug therapy | Skin Neoplasms - genetics | Cell Line, Tumor | Aged | Biomarkers, Tumor - genetics | Circulating Tumor DNA - blood | Mutation | Programmed Cell Death 1 Receptor - immunology | anti-programmedcelldeath-1antibody | circulatingtumourDNA | dropletdigitalPCR
Journal Article